Clinical Trial Update: Hypofractionation Radiotherapy in Combination with Glofitamab in Relapsed/refractory Diffuse B-cell Lymphoma with Baseline High Tumor Burden [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating hypofractionated radiotherapy in combination with glofitamab for relapsed/refractory diffuse large B-cell lymphoma with high tumor burd…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Lymphoma

Drugs mentioned

• Columvi (glofitamab) (glofitamab)

Snippet

Sponsor: Liling Zhang | Conditions: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Lymphoma | Phase 2 | Status: NOT_YET_RECRUITING